Related Experiment Video

Updated: Jul 6, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Addressing the future: combination with targeted therapies, adjuvant setting and beyond

Paul E Goss1

  • 1Massachusetts General Hospital Cancer Center, USA.

Anti-Cancer Drugs
|June 24, 2008
PubMed

Insights

Understanding endocrine therapy resistance in breast cancer is crucial. New targeted therapies combined with aromatase inhibitors (AIs) may offer improved outcomes for patients with resistant disease.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Mechanisms of endocrine therapy resistance, including de novo and acquired resistance, are being elucidated.
  • Aromatase inhibitors (AIs) are a standard adjuvant therapy, but resistance necessitates alternative strategies.
  • Improving patient outcomes beyond current AI treatments is a significant clinical challenge.

Purpose of the Study:

  • To explore potential treatment options for patients with endocrine therapy-resistant breast cancer.
  • To investigate strategies for overcoming resistance to endocrine therapy.
  • To review the role of targeted therapies in combination with AIs.

Main Methods:

  • Review of current understanding of resistance mechanisms.
  • Exploration of novel therapeutic targets and combinations.
  • Analysis of ongoing clinical trials investigating targeted therapies.

Main Results:

  • Emerging understanding of de novo and acquired resistance pathways.
  • Identification of targeted therapies as potential alternatives or adjuncts to AIs.
  • Clinical trials are evaluating combinations of targeted therapies and AIs.

Conclusions:

  • Simultaneous or sequential blockade of endocrine and other pathways is a promising approach.
  • Targeted therapies, alone or with AIs, hold potential for improving clinical outcomes.
  • Future breast cancer treatment will be shaped by ongoing clinical trial results.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...